Impact of specialist led integrated care in COPD
Research type
Research Study
Full title
The impact of specialist led integrated care on guideline adherence and outcomes in COPD
IRAS ID
228859
Contact name
Alice Turner
Contact email
Sponsor organisation
Heart of England NHS Foundation Trust
Duration of Study in the UK
2 years, 5 months, 31 days
Research summary
This study will look at the impact of care delivery by a specialist respiratory doctor compared to general practitioners for patients with COPD in East Birmingham. It will be run from the Heart of England Foundation Trust, which will provide the specialist input and oversight, and up to 40 practices across the Eastern Birmingham Health Organisation with approximately 2200 patients with COPD confirmed by their current medical practitioner. Each practice will be randomised to either the intervention or control group. The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations. Treatment will be at the discretion of the clinician and is not specified in the trial protocol. We anticipate that the treatment recommendations in the intervention arm may include referral to pulmonary rehabilitation and reduction in the use of inhaled corticosteroids, which are prescribed at high rates in our locality. The control group will be seen by the usual staff at their practice. They will not be seen by the trial team and their data will be extracted remotely using electronic systems.
The primary outcome will be to compare the rates of provision of guideline-based care in intervention and control practices. Secondary outcomes will include: referral to secondary care, unscheduled healthcare consultations (ED attendance, hospital admissions), COPD exacerbations, healthcare costs, medications prescribed, biochemical markers of disease, radiological investigations, lung function tests measured when clinically indicated, and death within 12 month follow-up period.REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
17/WM/0342
Date of REC Opinion
2 Oct 2017
REC opinion
Favourable Opinion